Trial Profile

A Phase 2/3 Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID 19 (EVADE)

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 23 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adintrevimab (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms ADG20-PREV-001; EVADE
Sponsors Invivyd

Most Recent Events

26 Jun 2023 According to an Invivyd media release, the company believes it can leverage serum neutralizing titers and clinical protection data from this trial, along with its manufacturing platform, to support the accelerated development of VYD222 and a stream of mAb candidates.
21 Dec 2022 This trial has been completed in Czechia - SUKL according to European Clinical Trials Database record.
22 Nov 2022 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com